Ascendis Pharma Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
September 5, 2024 6:54 AM EDTOppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.
The analyst comments "We upgrade ASND to Outperform (from Perform) and assign a $180 PT ahead of 1) Yorvipath's US launch for hypoparathyroidism (to commence by 1Q25)... More
Ascendis Pharma (ASND) PT Lowered to $174 at Jefferies
September 4, 2024 5:18 AM EDTJefferies analyst Kelly Shi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $174.00 (from $196.00) while maintaining a Buy rating.
The analyst comments "Skytrofa experienced a revenue growth reversal in Q2 (26M; -58% Q/Q; -25% YoY) on an unexpected net price... More
Ascendis Pharma (ASND) PT Lowered to $180 at Goldman Sachs
September 4, 2024 5:06 AM EDTGoldman Sachs analyst Paul Choi lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $195.00) while maintaining a Buy rating.
The analyst comments "Miss for Skytrofa on the back of insurance contract resets and significant price pressure; focus remains on upcoming US... More
Ascendis Pharma (ASND) PT Lowered to $178 at Citi
September 4, 2024 4:57 AM EDTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $193.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 2Q24 financial results, missing Street estimates on topline revenue and GAAP EPS as the company made significant accounting... More
